未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study
Grigoleit, G. U.; Kluger, H.; Thomas, S.; Chesney, J. A.; Domingo-Musibay, E.; Sanmamed, M. F.; Medina, T.; Ziemer, M.; Whitman, E.; Finckenstein, F. Graf; Chou, J.; Wu, X.; Sulur, G.; Shi, W.; Sarnaik, A. 分享 收藏 Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 studylifileucel是一种一次性自体肿瘤浸润淋巴细胞 (TIL) 细胞疗法，在免疫检查点抑制剂和靶向治疗进展后的晚期黑色素瘤患者中的疗效和安全性: C-144-01研究连续队列的汇总分析Chesney, Jason; Lewis, Karl D.; Kluger, Harriet; Hamid, Omid; Whitman, Eric; Thomas, Sajeve; Wermke, Martin; Cusnir, Mike; Domingo-Musibay, Evidio; Phan, Giao Q.; Kirkwood, John M.; Hassel, Jessica C.; Orloff, Marlana; Larkin, James; Weber, Jeffrey; Furness, Andrew J. S.; Khushalani, Nikhil, I; Medina, Theresa; Egger, Michael E.; Finckenstein, Friedrich Graf; Jagasia, Madan; Hari, Parameswaran; Sulur, Giri; Shi, Wen; Wu, Xiao; Sarnaik, Amod 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
OAAI